Compare SMID & LCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SMID | LCTX |
|---|---|---|
| Founded | 1960 | 1990 |
| Country | United States | United States |
| Employees | 188 | N/A |
| Industry | Building Materials | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 128.8M | 255.4M |
| IPO Year | 1996 | 1996 |
| Metric | SMID | LCTX |
|---|---|---|
| Price | $24.11 | $0.97 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $6.25 |
| AVG Volume (30 Days) | 9.6K | ★ 1.2M |
| Earning Date | 04-14-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 62.76 | N/A |
| EPS | ★ 0.51 | N/A |
| Revenue | ★ $93,446,000.00 | $14,556,000.00 |
| Revenue This Year | N/A | $109.40 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $47.61 | ★ N/A |
| Revenue Growth | 19.03 | ★ 53.24 |
| 52 Week Low | $23.51 | $0.91 |
| 52 Week High | $42.15 | $2.09 |
| Indicator | SMID | LCTX |
|---|---|---|
| Relative Strength Index (RSI) | 35.90 | 42.53 |
| Support Level | $23.51 | N/A |
| Resistance Level | $25.25 | $1.18 |
| Average True Range (ATR) | 0.74 | 0.06 |
| MACD | 0.06 | -0.00 |
| Stochastic Oscillator | 14.35 | 37.11 |
Smith-Midland Corp through its subsidiaries invents, develops, manufactures, markets, sells, and installs precast concrete products for primary use in the construction, highway, utilities, and farming industries. The firm's customers are general contractors and federal, state, and local transportation authorities. Its products include Slenderwall, JJhooks, Softsound, Sierra Wall and Easi set. A substantial portion of the company's business is derived from local, state, and federal building projects. The company generates revenues predominantly from the sale, leasing, licensing, shipping, and installation of precast concrete products for the construction, utility, and farming industries.
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline currently includes: OpRegen, OPC1, ReSonance, ILT1, RND1, PNC1, and LCT-CON. Its programs are based on its proprietary, in-house, cell-based manufacturing platform, which it call AlloSCOPE (Allogeneic, Scalable, Consistent, Off-the-shelf, Pluripotent Cell Engineering), and supported by its associated development, formulation, manufacturing, and delivery capabilities. The AlloSCOPE platform is a proprietary differentiation and production modality from which, a single, well-characterized pluripotent cell line can create a stable current Good Manufacturing Practice, master cell bank.